How should I start and manage Journavx (suvetrigine) therapy, including dose, timing relative to meals, drug interactions, side effects, and alternative pain options?

Starting and Managing Journavx (Suzetrigine) Therapy

Start Journavx with a 100 mg loading dose on an empty stomach (at least 1 hour before or 2 hours after food), then give 50 mg every 12 hours starting 12 hours after the initial dose—these maintenance doses can be taken with or without food. 1

Dosing Algorithm

Standard Dosing (Normal Hepatic Function, No CYP3A Inhibitors)

• Dose 1 (Loading): 100 mg orally on empty stomach

  • Wait at least 1 hour before eating or take 2 hours after food
  • Clear liquids allowed (water, apple juice, vegetable broth, tea, black coffee)
  • This fasting requirement is critical—food delays onset of action 1

• Dose 2 onward: 50 mg every 12 hours

  • Start 12 hours after loading dose
  • Can take with or without food 1

Modified Dosing for Moderate Hepatic Impairment (Child-Pugh B)

• Doses 1-4: Same as standard (100 mg loading, then 50 mg every 12 hours for 3 doses)
• Dose 5 onward: Reduce to 50 mg every 24 hours 1

Modified Dosing with Moderate CYP3A Inhibitors

• Doses 1-4: Same as standard (100 mg loading, then 50 mg every 12 hours for 3 doses)
• Dose 5 onward: Reduce to 50 mg every 24 hours 1

Contraindicated Situations

• Severe hepatic impairment (Child-Pugh C): Avoid use entirely 1
• Strong CYP3A inhibitors: Absolute contraindication 1

Timing Relative to Meals

The loading dose timing is non-negotiable—the empty stomach requirement for the first 100 mg dose is specifically to avoid delayed onset of action 1. After the loading dose, all subsequent 50 mg doses can be taken without regard to meals, providing flexibility for the patient 1.

Avoid grapefruit in any form (food or drink) throughout treatment—grapefruit is a moderate CYP3A inhibitor that will increase drug exposure 1.

Critical Drug Interactions

Absolute Contraindications (Strong CYP3A Inhibitors)

Do not prescribe Journavx with:

• Ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat
• These dramatically increase suzetrigine levels and risk of adverse effects 1

Require Dose Reduction (Moderate CYP3A Inhibitors)

Reduce to once-daily dosing after first 4 doses with:

• Erythromycin, diltiazem, verapamil, fluconazole, grapefruit
• These moderately increase drug exposure 1

Journavx Reduces Efficacy of Other Drugs (CYP3A Induction)

Suzetrigine induces CYP3A enzymes, which reduces levels of many medications 1. Critical interactions include:

Hormonal contraceptives: This is a major pitfall. Patients on hormonal contraceptives containing progestins other than levonorgestrel or norethindrone must:

• Add barrier contraception (condoms) during treatment AND for 28 days after stopping Journavx, OR
• Switch to combined oral contraceptives with ethinyl estradiol plus levonorgestrel/norethindrone, OR
• Use intrauterine system 1

Other sensitive CYP3A substrates may lose efficacy:

• Immunosuppressants (tacrolimus, cyclosporine)
• Anticoagulants (apixaban, rivaroxaban)
• Statins (simvastatin, atorvastatin)
• Refer to prescribing information for these drugs when co-prescribing 1

Duration of Treatment

Use for the shortest duration consistent with pain control—studies have not evaluated use beyond 14 days 1. This is approved specifically for moderate to severe acute pain, not chronic pain 1, 2.

In clinical trials, 83-91% of patients rated pain control as good to excellent, with most requiring treatment for less than 14 days 3.

Missed Dose Management

Standard Dosing Schedule

• One missed dose: Take as soon as remembered, then resume regular schedule
• Two or more missed doses: Take 100 mg (loading dose), then resume regular schedule 1

Modified Dosing (Hepatic Impairment or Moderate CYP3A Inhibitors)

• Take missed dose as soon as remembered
• If next scheduled dose is within 6 hours, skip that dose and resume with subsequent dose 1

Expected Side Effects

Suzetrigine has a favorable safety profile compared to opioids—no CNS depression, no respiratory depression, no addiction potential because it does not cross the blood-brain barrier 2, 4.

In clinical trials:

• Most adverse events were mild (27.7%) or moderate (8.2%)
• No serious CNS effects, sedation, or withdrawal symptoms
• Well-tolerated across diverse surgical and non-surgical pain conditions 3

Common side effects are generally mild and self-limited 5, 2, 3.

Alternative Pain Management Options

When Journavx is contraindicated or insufficient, consider these evidence-based alternatives:

Non-Opioid Options

• NSAIDs + Acetaminophen: First-line for acute pain when not contraindicated 6
  • Ibuprofen 400-800 mg every 6 hours (max 2.4 g/day)
  • Naproxen 275-550 mg every 6-12 hours (max 1.5 g/day)
  • Ketorolac 60 mg IM for severe pain (max 5 days) 7

Opioid Options (When Non-Opioids Inadequate)

• Immediate-release morphine: 5-15 mg oral for opioid-naïve patients 8
• Hydrocodone/acetaminophen: Comparable efficacy to Journavx 50 mg in trials 4, 3
• Tramadol: 50-100 mg every 4-6 hours (max 400 mg/day) 8

Critical opioid principles if needed:

• Prescribe lowest effective dose for shortest duration (often 3 days or less) 9
• Avoid concurrent benzodiazepines 9
• Offer naloxone for overdose risk factors 9
• Avoid meperidine and mixed agonist-antagonists (butorphanol, pentazocine) 8

Multimodal Approach

Combine Journavx with non-opioid adjuncts for enhanced analgesia:

• Acetaminophen for additive analgesia 6
• Ice, elevation, compression for surgical pain
• Regional anesthesia techniques when appropriate

Common Pitfalls to Avoid

1. Taking loading dose with food: This delays onset—emphasize empty stomach for first dose only 1

2. Missing contraceptive counseling: Failure to address hormonal contraceptive interactions leads to unintended pregnancy risk—counsel about 28-day washout period 1

3. Prescribing with strong CYP3A inhibitors: This is an absolute contraindication that increases adverse event risk 1

4. Forgetting grapefruit restriction: Even grapefruit juice acts as moderate CYP3A inhibitor requiring dose adjustment 1

5. Using beyond 14 days: No safety/efficacy data beyond 2 weeks—this is for acute pain only 1

6. Not adjusting for hepatic impairment: Moderate impairment requires once-daily dosing after day 2; severe impairment is contraindicated 1

7. Expecting opioid-level analgesia immediately: Journavx provides comparable but not superior analgesia to hydrocodone/acetaminophen—set realistic expectations 4, 3